Tolerance and efficacy of azathioprine in pediatric Crohn's disease

Inflammatory Bowel Diseases

Volumn 17, Issue 10, 2011, Pages 2138-2143

  Riello, Laura ^a   Talbotec, Cécile ^a   Garnier Lengliné, Hélène ^a,b   Pigneur, Bénédicte ^a,b   Svahn, Johan ^a   Canioni, Danielle ^a,b   Goulet, Olivier ^a,b   Schmitz, Jacques ^a,b   Ruemmele, Frank M ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

azathioprine; pediatric Crohn's disease; thiopurine methyl transferase

Indexed keywords

AZATHIOPRINE; METHYLTRANSFERASE; THIOPURINE METHYL TRANSFERASE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CROHN DISEASE; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GENERAL WEAKNESS; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; OBSERVATIONAL STUDY; PANCREATITIS; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SEPTIC SHOCK; SKIN ALLERGY; VIRUS INFECTION; VOMITING;

ADOLESCENT; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROHN DISEASE; ENTERAL NUTRITION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MAXIMUM TOLERATED DOSE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052749309     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21612     Document Type: Article

References (28)

1. Fiocchi C,. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998; 115: 182-205.
2. Abraham C, Cho JH,. Inflammatory bowel disease. N Engl J Med. 2009; 361: 2066-2078.
3. Baldassano RN, Piccoli DA,. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am. 1999; 28: 445-158.
4. Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009; 1: CD000067.
5. Prefontaine E, Macdonald JK, Sutherland LR,. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2010; 6: CD000545.
6. Fraser AG, Orchard TR, Jewell DP,. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002; 50: 485-489.
7. Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis. 2009; 15: 375-382.
8. Reinisch W, Panés J, Lémann M, et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol. 2008; 103: 2284-2292.
9. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995; 37: 674-678.
10. Derijks LJ, Gilissen LP, Hooymans PM, et al. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006; 24: 715-729.
11. Punati J, Markowitz J, Lerer T, et al., Pediatric IBD Collaborative Research Group. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis. 2008; 14: 949-954.
12. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000; 119: 895-902.
13. Jaspers GJ, Verkade HJ, Escher JC, et al. Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm Bowel Dis. 2006; 12: 831-836.
14. Martínez F, Nos P, Pastor M, et al. Adverse effects of azathioprine in the treatment of inflammatory bowel disease. Rev Esp Enferm Dig. 2001; 93: 769-778.
15. Kirschner BS,. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology. 1998; 115: 813-821.
16. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54: 1121-1125.
17. Fraser AG, Orchard TR, Robinson EM, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002; 16: 1225-1232.
18. Kader HA, Wenner WJ Jr, Telega GW, et al. Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol. 2000; 30: 409-413.
19. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000; 118: 1025-1030.
20. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis - the Porto criteria. J Pediatr Gastroenterol Nutr. 2005; 41: 1-7.
21. Hyams J, Markowitz J, Otley A, et al., Pediatric Inflammatory Bowel Disease Collaborative Research Group. Evaluation of the Pediatric Crohn Disease Activity Index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005; 41: 416-421.
22. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991; 12: 439-447.
23. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55: 749-753.
24. Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 1999; 117: 527-535.
25. Verhave M, Winter HS, Grand RJ,. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr. 1990; 117: 809-814.
26. Markowitz J, Grancher K, Kohn N, et al. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000. Am J Gastroenterol. 2002; 97: 928-932.
27. Velayos FS, Sandborn WJ,. Use of azathioprine and 6MP in postoperative Crohn's: changing natural history or just along for the ride? Am J Gastroenterol. 2009; 104: 2097-2099.
28. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol. 2009; 104: 2089-2096.